1. Scrip

Bayer Sees Significant, But Smaller, Asundexian Opportunity

BMS Still Confident In Competing Asset Milvexian

 
• By Mandy Jackson

Scrip spoke with Bayer’s head of pharma R&D Christian Rommel at the J.P. Morgan Healthcare Conference about the road ahead for Factor XIa inhibitor asundexian after its atrial fibrillation setback.

Heart activity on monitor in intensive care unit
Bayer sees significant opportunity for asundexian in stroke despite AF miss • Source: Shutterstock

At the J.P. Morgan Healthcare Conference in 2023, Bayer AG forecast that four commercial and late-stage products would generate peak revenues totaling €12bn, including €5bn alone from Factor XIa inhibitor asundexian for atrial fibrillation (AF) and stroke and €1bn for neurokinin-1,3 (NK-1,3) receptor antagonist elinzanetant for vasomotor symptoms in women going through menopause. A year later, the company has positive Phase III results for elinzanetant, but after suffering a setback for asundexian.

Bayer reported positive results for two Phase III clinical trials of elinzanetant on opening day of J.P. Morgan 2024 in...

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.